AACR issues 12th annual cancer progress report

September 21 2022

Considerable progress has been made to improve, extend, and save lives

of patients with cancer in the last year, according to the 12th annual *Cancer Progress Report* released by the American Association for Cancer Research (AACR).

Researchers from the AACR present recent advances affecting cancer patients, highlighting progress made from Aug. 1, 2021, to July 31, 2022, and focusing on cancer incidence, mortality, and survivorship statistics as well as the latest research.

According to the report, the number of cancer survivors reached more than 18 million in the United States as of Jan. 1, 2022. The age-adjusted overall cancer death rate has decreased steadily since the 1990s, with a 2.3 percent decrease every year from 2016 to 2019. Across the clinical cancer care continuum, eight new anticancer therapeutics were approved by the U.S. Food and Drug Administration, including the first drug for treating uveal melanoma and a first molecularly targeted therapeutic for Von Hippel-Lindau syndrome. In addition, the use of 10 anticancer therapeutics was expanded and two new diagnostic imaging agents were approved. Several artificial intelligence-based tools have been developed for improving detection and diagnosis of cancers.

"Targeted therapies, immunotherapy, and other new therapeutic approaches being applied clinically all stem from fundamental discoveries in basic science," Lisa M. Coussens, Ph.D., president of the AACR, said in a statement. "Investment in cancer science, as well as support for science education at all levels, is absolutely essential to drive the next wave of discoveries and accelerate progress."

More information: AACR Cancer Progress Report 2022

Copyright © 2022 HealthDay. All rights reserved.

Citation: AACR issues 12th annual cancer progress report (2022, September 21) retrieved 25 April 2024 from https://medicalxpress.com/news/2022-09-aacr-issues-12th-annual-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.